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  The levels of tartrate resistant acid phosphatase (TRAP), 
matrix metalloproteinase-2 (MMP-2), and tissue inhibitor 
of matrix metalloproteinase-2 (TIMP-2) in synovial fluid 
(SF) and serum in cases of canine osteoarthritis (OA) were 
measured. OA was induced by a surgically-created medial 
patellar luxation in the left stifle of 24 dogs. SF and blood 
samples  were  collected  at  1.5-  and  3-month  intervals, 
respectively. Every 3 months, one dog was euthanatized to 
collect tissue samples from both stifles. TRAP levels in SF 
and serum were measured using a spectrophotometer, and 
TRAP-positive  cells  in  joint  tissues  were  identified  by 
e n z y m e  h i s t o c h e m i s t r y .  M M P - 2  a n d  T I M P - 2  i n  S F  a n d  
serum  were  detected  by  Western  blotting  and  ELISA, 
respectively. TRAP in SF from the stifles and serum was 
significantly increased (p ＜ 0.05) after 3 months. TIMP-2 
in SF and serum was significantly decreased (p ＜ 0.05), 
whereas MMP-2 in SF was significantly increased (p ＜ 0.05) 
during the progression of OA. Histochemistry revealed an 
increased number of TRAP-positive cells in tissues from 
OA-affected joints. Assays measuring TRAP, MMP-2, and 
TIMP-2  in  SF  and  serum,  and  methods  that  detect  in-
creased numbers of TRAP-positive cells in the joint tissues 
can play an important role in identifying the early phases 
of degenerative changes in canine joint components.
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Introduction
Patellar luxation (PL) is one of the most common 
orthopedic disorders in dogs [18]. PL can result in the 
development of degenerative joint disease, pain, and 
lameness. It has been reported that medial patellar luxation 
(MPL) increases the stress on the cranial cruciate ligament 
(CCL), predisposing the structure to degeneration and 
rupture. Secondary osteoarthritis (OA) is a common result 
of MPL [20].
OA is a slowly progressive disease with different 
etiologies that finally converge on the same pathogenic 
pathway that is hallmarked by characteristic changes in 
cartilage, subchondral bone, and synovial membrane. The 
insidious onset and “silent” progression of OA not only 
prevent early diagnosis of this disease, but also delay 
treatment that may help prevent further cartilage destruction 
and joint failure [16]. Hence, determinants or markers that 
may be used to detect and monitor molecular events early in 
the pathogenesis of OA are of considerable interest as to 
detect preclinical disease, determine prognosis, and monitor 
the response to drugs and therapy [10].
Although the cause of the synovial inflammation 
associated with OA is unknown, recent work has shown 
that the synovial intima contains large numbers of 
dendritic cells and macrophage-like cells, which express 
tartrate-resistant acid phosphatase (TRAP), together with 
increased immunoglobulin deposition [17]. TRAP- 
positive mononuclear cells within the synovium typically 
express many degradative collagenolytic enzymes 
including cathepsin K, cathepsin S, and matrix 
metalloproteinases  (MMPs). The presence of TRAP- 
positive cells within the synovium is a characteristic 
feature of arthritis, and is considered to be a key factor for 
promoting progressive and irreversible articular cartilage 
and joint destruction [23]. Production of MMPs, 
cathepsins, and TRAP at sites of inflammation potentially 
contributes to articular cartilage matrix degradation [8,23]. 
It is well documented that osteoblasts express and secrete 
a large amount of TRAP. This factor has been shown to be 
a useful histochemical marker for identifying osteoclasts 
and a biochemical index for osteoclastic resorption [9,11].
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various types of arthritis, including rheumatoid arthritis 
(RA) and OA, and is a major cause of joint dysfunction. Two 
pathways are known to be involved in the destruction of 
cartilage. The first is an intrinsic pathway by which the 
chondrocytes themselves degrade cartilage extracellular 
matrix (ECM). The second is an extrinsic pathway through 
which tissues or cells other than chondrocytes, such as 
inflamed synovium, pannus tissue, or infiltrating inflam-
matory cells break down the ECM of cartilage through 
synovial fluid (SF). In both pathways, enzymatic digestion 
of the ECM results in cartilage destruction [25]. Many 
proteinases are expressed in joint tissues of patients with RA 
and OA. Among these, MMPs are believed to have a key 
role in the arthritic joint destruction. MMP production in 
fibroblasts, macrophages, and chondrocytes is mediated by 
synovial macrophages and lymphocytes. MMPs are the 
proteases that participate in ECM degradation and remo-
deling. The proteolytic activity of MMPs is regulated by 
specific inhibitors known as tissue inhibitors of metallo-
proteinases (TIMPs) [1,15]. The N-terminal domain of the 
TIMP molecule competitively binds to the active site of 
MMPs at a 1 : 1 ratio to form a non-covalent complex that 
abolishes MMP activity. TIMP-2 is the major TIMP 
expressed in fibroblasts, macrophages, and endothelial 
cells, and potently inhibits most MMPs [1,5,24].
A good biological marker of OA would be sensitive to 
changes in the severity of cartilage destruction. Identi-
fication of a single predictive marker is probably an 
unrealistic goal [4]. Current research efforts are focused on 
identifying combinations of several markers capable of 
providing information about the extent of cartilage 
degradation and remodeling, subchondral bone metabolism, 
and reactive changes in synovial and CCL tissues. 
However, to the best of our knowledge there is currently a 
lack of evidence in the literature about TRAP, MMP-2, and 
TIMP-2 concentrations in the SF and serum in the MPL 
model of OA in dogs. In order to better understanding the 
pathophysiology of OA and to identify possible biomarkers 
of early OA, the levels of TRAP and TIMP-2 in the serum 
and SF, as well as the level of MMP-2 in the SF, were 
assayed in the present study. It was hypothesized that there 
would be differences of the levels of these markers in the 
SF and serum of normal dogs and dogs with experimen-
tally-induced OA. 
The purpose of this study was to investigate whether the 
early phases of degenerative changes that commence after 
the onset of MPL can be identified by monitoring changes 
in the concentration of TRAP, MMP-2, and TIMP-2.
Materials and Methods
Experimental animals
Twenty-four skeletally-mature, healthy, mixed small 
breed dogs of both genders, age 2 to 6 years and weighing 
2.8 to 9 kg, were used for this experiment. The experi-
mental dogs were purchased from the Preclinical Research 
Center (Chemon, Korea). The animals were kept in 
quarantine for 1 month and acclimated in cage con-
finement. Before participating in the experiment, physical 
and radiographic examinations were performed to ensure 
the absence of neurologic disease, patellar luxation or 
other orthopedic diseases, or to determine the animals had 
previously undergone surgical procedures involving either 
hind limb. The dogs were housed in individual cages in the 
departmental animal shed at the Department of Surgery, 
College of Veterinary Medicine, Chonbuk National 
University, Korea. They were fed a standard commercial 
diet (Precept, USA) and had access to water ad libitum.
Anesthesia surgery and postoperative care
After the animals were premedicated with atropine sulfate 
(0.05 mg/kg, SC; Dai Han Pharm, Korea), anesthesia was 
induced with thiopentone sodium (25 mg/kg, IV; Dai Han 
Pharmaceutical, Korea) and maintained with enflurane and 
oxygen delivered through a cuffed endotracheal tube. 
In all of the experimental animals (n = 24), left stifle 
arthrotomy was performed using a standard parapatellar 
approach.  An incision was made through the fascia lata 
just lateral to the patellar ligament. The joint was 
thoroughly examined to evaluate the condition of the 
cruciate ligaments and menisci. MPL was induced by 
placing purse string sutures around the parapatellar 
fibrocartilage and anchoring the patella to the fabellar 
ligament using monofilament sterile nylon sutures. Medial 
retinacular reinforcement (imbrication) and lateral release 
were also performed to interfere with the neutral tracking 
of the patella. Dogs in the sham group (n = 12) underwent 
sham operation on their right stifles, whereas animals in 
the non-surgical control group (n = 12) remained intact. 
For the sham operation, a scalpel blade was inserted into 
the right stifle through a lateral parapatellar stab incision to 
inflict minor trauma to the synovium while the other joint 
components remained intact. 
Post-surgically, the animals were kept in close observa-
tion in a postoperative room and were administered 
cephalexin (25 mg/kg, IV; Union Korea Pharmaceutical, 
Korea) every 8 h, for 5 days and dexamethasone (0.2 
mg/kg, IV; Daewon Pharmaceutical, Korea) every 6 h for 3 
days. The external stitches were removed after the surgical 
wounds healed, and the animals were moved to the 
experimental animal shed after 10 days.
Collection of SF
SF specimens were collected preoperatively and post-
operatively at 1.5 month intervals from both stifles (index 
and contralateral). As much SF was collected as possible 
(0.2∼0.45 mL) by arthrocentesis from the stifle joint and 
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After noting the volume and appearance of the SF, the 
specimens were centrifuged at 12,000 × g for 10 min at 4
oC 
to remove the cells, and the supernatant was stored at 򰠏 80
oC 
until biomarker assays were performed.
Collection and preservation of serum
Blood samples were collected prior to and 3, 6, 9, and 12 
months after experimental induction of OA, and subjected 
to TRAP and TIMP-2 assays. Three mL of blood samples 
from each animal were collected using a 5 mL disposable 
syringe (Hwajin Medical, Korea) and transferred to sterile 
screw-capped tubes without anticoagulant (Soyagreentec, 
Korea), left undisturbed at room temperature for 1 h to 
permit coagulation, and centrifuged at 1,500 × g for 15 
min. The serum was collected and transferred to Eppendorf 
tubes and stored at 򰠏 80
oC until it was used for the assays.
TRAP assay for SF and serum
TRAP activity in the SF and serum specimens was 
measured using a biochemical assay in 96-well plates with 
para-nitrophenylphosphate (pNPP) (Sigma-Aldrich, USA) 
as a substrate. All reagents for this assay were purchased 
from a commercial supplier. To reduce sample viscosity 
and improving pipetting accuracy, the SF specimens were 
digested with 50 IU/mL of streptomyces hyaluronidase 
(Sigma-Aldrich, USA) at at 37
oC for 30 min prior to the 
assay. The serum specimens were also incubated at 37
oC 
without streptomyces hyaluronidase for 30 min to inacti-
vate the acid phosphatase activity of the erythrocytes. All 
of the SF and serum samples were diluted 1：4 with 0.9% 
NaCl before the assay. The 0.9% NaCl solution was used as 
the negative control. SF and serum samples (100 μL) were 
added to 100 μL of the reaction mixture so that the final 
incubation medium contained 2.5 mM pNPP, (ditris salt), 
0.1 M sodium acetate buffer, pH 5.8; 0.2 M KCl, 0.1% 
Triton X-100, 10 mM sodium tartrate, 1 mM ascorbic acid, 
and 100 μM FeCl3. The concentration of TRAP was 
determined using 200 μL of the final incubation medium 
per well in the 96-well plate (Immulon 2 HB Flat Bottom 
Microtiter Plate; Dynex Technologies, USA). After 
incubating the 96-well plate for 1 h at 37
oC, the liberated 
p-nitrophenol was converted to p-nitrophenolate by adding 
50 μL of 0.9 M NaOH, and the absorbance was measured 
at 405 nm using a spectrophotometer (Cess UV 90c; 
Bioteck, USA). One unit (U) of TRAP activity corres-
ponded to 1 mol of p-nitrophenol liberated per 1 min at 
37
oC. If the TRAP activity exceeded the range of the 
standard curve, the samples were further diluted and 
assayed.
TIMP-2 assay for the SF and serum
SF and serum samples were assayed for TIM-2 activity 
using a commercially available TIMP-2 Biotrak ELISA 
system (Amersham, UK). The samples were assayed 
according to the protocol provided by the kit manufacturer. 
Briefly, 100 μL of the prepared standard and 100 μL of each 
sample were incubated at 25
oC for 1 h with 100 μL of the 
anti-TIMP-2 peroxidase conjugate. The wells were then 
aspirated, washed, and incubated with 100 μL of tetra-
methylbezidine hydrogen peroxide at 25
oC for 30 min. 
This reaction was stopped by the addition of 1.0 M 
sulphuric acid and the optical density was measured at 450 
nm using a spectrophotometer (Cess UV 90c; Bioteck, 
USA). The concentrations of TIMP-2 were determined 
according to a standard curve and reported in ng/mL.
MMP-2 assay for the SF
SF samples (40 μL) were incubated in Laemmli sample 
buffer (LSB) with β-mercaptoethanol (40 μL), heated to 
90
oC for 5 min, and separated by SDS polyacrylamide gel 
electrophoresis on 4∼20% Tris-glycine gradient gels 
(Bio-Rad Laboratories, USA). A sample of human MMP-2 
protein (3 μL; Sigma-Aldrich, USA) was mixed in LSB (3 
μL), heated to 90
oC for 5 min, and run on each gel as a 
control. The separated proteins were then electropho-
retically transferred to a polyvinylidene difluoride (PVDF) 
membrane (Sigma-Aldrich, USA) in a tank system with 
plate electrodes. The membranes were blocked for 1 h at 
25
oC in 5% non-fat dried milk in TBS-Tween, and then 
incubated in room temperature for 1 h with mouse 
monoclonal anti-MMP-2 antibody (1：1,000 dilution in 
TBS-Tween; Sigma-Aldrich, USA). After incubating, the 
membranes were washed four times with 0.1% TBS- 
Tween, and then incubated for 1 h at room temperature with 
a horseradish peroxide-conjugated secondary antibody 
(Amersham, UK) diluted 1 : 10,000 in TBS-Tween with 
0.1% Tween. After four washes with TBS-Tween, the 
immunoreactive bands were visualized with Pico chemi-
luminescent substrate (Pierce Biotechnology, USA) and 
the blots were exposed to radiographic film (Pierce 
Biotechnology, USA).
Histochemical staining of the joint tissues for TRAP
Histochemical staining to visualize TRAP expression 
was performed on 15 μm frozen sections of the CCL and 
synovium specimens as described by Muir et al. [17]. All 
reagents for histochemical staining were obtained from 
Sigma-Aldrich (USA). A solution of naphthol AS-BI 
phosphate was prepared by dissolving 25 mg of naphthol 
AS-BI phosphate in 2.5 mL of n,n-dimethylformamide to 
which 45 mL of 0.05 M Tris-maleate buffer (pH 5) was 
added. A solution of hexazotized pararosanaline was pre-
pared by dissolving 0.25 g of pararosaniline hydrochloride 
in 5 mL of distilled water and then adding 1.25 mL of 
hydrochloric acid. This solution was mixed with an equal 
volume of 4% sodium nitrite immediately before use. The 
final reaction mixture for histochemical staining was 
prepared by adding 4 mL of the hexazotized pararosanaline 276    Md. Rafiqul Alam et al.
Fig. 1.  Tartrate resistant acid phosphatase (TRAP) levels in the 
synovial fluid (SF) of the index and contralateral (control and 
sham) stifles after induction of osteoarthritis (OA) during 
different experimental periods.
Fig. 2. TRAP levels in the serum during different experimental 
periods after inducing OA secondary to medial patellar luxation 
(MPL).
Fig. 4. TIMP-2 levels in the serum at different experimental 
periods after inducing OA secondary to MPL.
Fig. 3. Tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) 
levels in the SF of the index and contralateral (control and sham)
stifles during different experimental periods after OA induction.
solution to the naphthol AS-BI phosphate solution along 
with 50 mM sodium-potassium tartrate. The final reaction 
mixture was filtered using syringe filters (Nalge, USA) 
before use. The 15 μm thick sections were incubated in the 
reaction mixture at 37
oC for 1∼2 h, rinsed in distilled 
water, counterstained with Mayer’s hematoxylin, and 
mounted. For each batch of slides, a negative control was 
prepared by omitting the naphthol AS-BI phosphate. The 
CCL and synovium specimens were examined by light 
microscopy for presence of the cells that contained TRAP. 
Statistical analysis
The Western blots were scanned using a digital imaging 
system (Fusion FX7; Vilber Lourmat, Germany) and the 
relative intensity of the bands was determined by 
densitometry (Bio-Rad Laboratories, USA). The data 
obtained in the present study were analyzed using an 
ANOVA and Student’s t-test. A p value ＜ 0.05 was 
considered to be statistically significant. The data are 
presented as the mean ± SD.
Results
Changes in the levels of TRAP in the SF and serum
The level of TRAP in the SF in OA-induced stifles 
increased significantly (p ＜ 0.05) 3 months postoperatively 
in comparison to that of the pre-surgical control, 
post-surgical contralateral control and sham-operated 
stifles. This elevated level was sustained throughout the 
experimental period (Fig. 1). The serum level of TRAP 
was found to be increased 3 months postoperatively and Biomarkers of the early phases of osteoarthritis    277
Fig. 6. Microphotographs of the stained frozen synovium 
section. The red mononuclear cells (arrow) are positive for 
TRAP. (A) Control. (B) OA 3 month. (C) OA 6 month. (D) OA 12
month. Scale bars = 100 μm.
Fig. 7. Microphotographs of the stained frozen cranial cruciate 
ligament (CCL) section. The red mononuclear cells (arrow) are 
positive for TRAP. (A) Control. (B) OA 3 month. (C) OA 6 
month. (D) OA 12 month. Scale bars = 100 μm.
Fig. 5. Western blot showing matrix metalloproteinase-2 
(MMP-2) levels in the SF during different experimental periods 
after the induction of OA secondary to MPL.
Fig. 8. Microphotographs of the stained frozen articular cartilage 
section. The red mononuclear cells (arrow) are positive for TRAP.
(A) Control. (B) OA 12 month. Scale bars = 100 μm.
was significantly increased (p ＜ 0.05) 6 months after the 
induction of OA (Fig. 2).
C h a n g e s  i n  t h e  l e v e l s  o f  T I M P - 2  i n  t h e  S F  a n d  
serum
The level of TIMP-2 in the SF collected from OA-induced 
stifles was significantly decreased (p ＜ 0.05) 3 months 
postoperatively compared to the pre-surgical control, 
post-surgical contralateral control, and sham-operated 
stifles (Fig. 3). The serum level of TIMP-2 was decreases 3 
months postoperatively and significantly decreased (p ＜ 
0.05) 6 months after the induction of OA (Fig. 4).278    Md. Rafiqul Alam et al.
Changes in the levels of MMP-2 in the SF
The level of MMP-2 in the SF was found to increase 
significantly (p ＜ 0.05) on 3 months after induction of OA 
and the levels observed on the subsequent experimental 
period were significantly (p ＞ 0.05) above the control 
value (Fig. 5).
TRAP histochemistry
Histochemical staining specific for TRAP revealed the 
presence of TRAP-positive cells in the synovium, CCL, 
and cartilage 3 months postoperatively in the OA-induced 
stifles but not in the contralateral control or sham-operated 
stifles (Figs. 6∼8). The synovium, CCL, and cartilage 
collected from the index stifles after 6 and 12 months of 
OA induction showed markedly increased numbers of 
TRAP-positive cells. Moderate synovial inflammation is 
also seen as mononuclear cell infiltration into the syno-
vium. However, the contralateral control and sham- 
operated stifles also showed a mild increase in the number 
of TRAP-positive cells in the synovium and CCL tissues 
during the later stage of OA.
Discussion
OA is a disease with many complex etiologies and affects 
all adjacent tissues in diarthrodial joints [21]. Mor-
phological, biochemical, structural, and biomechanical 
changes of the ECM and cells are observed in cases of OA 
which lead to the degeneration of articular cartilage with 
softening, fibrillation, ulceration, and loss of cartilage 
tissues. Since the functionality of diarthrodial joints cannot 
be sustained without articular cartilage, the precise and 
early diagnosis of OA is fundamental to preventing or 
reducing long-term disability. Since the degenerative 
processes that lead to OA begin long before clinical 
manifestations of the disease, early diagnosis of OA is 
challenging [7,16]. Recently, investigations have focused 
on finding SF or serum biomarkers that may be useful for 
diagnosing, monitoring treatment efficacy, or determining 
prognosis for patients with OA [7].
TRAP contains a binuclear iron center with two iron 
molecules, one that is redox-active and the other that 
stabilizes the ferric form. In addition to its phosphatase 
activity, TRAP is also capable of producing reactive 
oxygen species (ROS) through Fenton’s reaction in which 
the redox-active ferrous iron reacts with hydrogen 
peroxide to generate highly destructive hydroxyl radicals. 
This activity has been detected by three different 
laboratories using three different methods [8,22]. ROS 
generated by TRAP are capable of destroying type I 
collagen, the main protein in bone matrix. Macrophages 
overexpressing TRAP increase the amounts of intracellular 
ROS, suggesting that the enzyme is capable of producing 
ROS in vivo [8]. ROS generation is optimal at a neutral pH, 
distinguishing this process from phosphatase activity that 
is optimal at an acidic pH [12]. This suggests that these two 
activities may function in different intracellular com-
partments, and that the pH of the environment may 
determine which activity is involved. Mutant TRAP 
enzymes that are completely inactive as phosphatase are 
capable of producing ROS, indicating that these two 
activities are functionally independent. In the present 
study, the significant increase in the level of TRAP in SF 
and serum as well as increased numbers of TRAP-positive 
cells in the joint tissues during the early stage of OA 
indicated that TRAP might have a potential role in the 
pathogenesis of this disease [14]. 
TIMPs are known as endogenous protease inhibitors that 
bind to active MMPs at a 1 : 1 molar ratio [1,3,15]. 
Although the pathogenesis of OA is not fully understood, 
MMPs derived from chondrocytes, synovium, and 
polymorphonuclear leukocytes have been proposed to play 
a major role in cartilage degradation seen in cases of OA. 
The balance between MMPs and TIMPs is tightly 
controlled in healthy joints. However, in OA, the amount 
of MMPs exceeds the locally-available levels of TIMPs, 
resulting in excessive ECM degradation [6,19]. The 
N-terminal domain of the TIMP molecule competitively 
binds to the active site on the MMP enzyme at a 1 : 1 ratio 
to form a non-covalent complex that abolishes MMP 
activity. TIMP-2 is the major TIMP expressed by 
fibroblasts, macrophages, and endothelial cells, and 
potently inhibits most MMPs [1,5,24]. Significant 
increases in MMP-2 levels with a simultaneous decrease in 
TIMP-2 levels in the SF observed in the present study 
suggested a disruption in the balance of these two enzymes, 
thereby indicated a high rate of turnover in articular 
cartilage. These findings are in agreement with those of 
previous reports [14,21,25]. Decreased serum levels of 
TIMP-2 with the progression of the disease further 
correlated with the levels of this enzyme in the SF. This 
finding contrasts with the report by Salinardi et al. [21], but 
is in complete agreement with the report by Klimiuk et al. 
[13].
The ELISA ‘sandwich’ system used for this study to 
measure TIMP-2 concentrations recognized both free 
TIMP-2 and enzyme that was complexed with the active 
form of MMPs. The immunoreactivities of free and 
complexed TIMP-2 were 100% and 330%, respectively. 
This ELISA did not recognize TIMP-1 or -3; therefore, 
cross-reactivity with other TIMPs was very low. The 
ELISA used to measure TIMP-2 is capable of quantifying 
TIMP-2 with a sensitivity defined as two standard 
deviations above the mean optical density. The TIMP-2 
peptide epitopes used to produce antibodies for the ELISA 
are conserved across different species. Therefore, the assay 
should recognize TIMP-2 from all species including 
human, mouse, rat, dog, guinea pig, and cow [2,5].Biomarkers of the early phases of osteoarthritis    279
Changes in the SF and serum levels of TIMP-2 and SF 
levels of MMP-2 found during different periods after OA 
induction indicates that these enzymes may be involved in 
the pathogenesis of OA. This finding may provide infor-
mation about the progression and degree of degenerative 
changes during the disease process. However, this idea 
cannot be concluded strictly as the pathogenesis and 
mechanism, how the degenerative changes occur is not yet 
clearly understood. The findings regarding the changes in 
the levels of TIMP-2 and MMP-2 with the progression of 
OA is much informative to support them as biomarkers for 
the detection of the early stages of the disease. Never-
theless, the results of this study broaden the knowledge 
about TRAP, MMP-2 and TIMP-2, and suggest the 
necessity for further studies to explore the role of these 
enzymes as therapeutic targets for treating canine OA. The 
changes in the levels of TRAP, MMP-2 and TIMP-2 in the 
SF and serum with OA progression as well as the presence 
of TRAP-positive cells in the joint tissues imply that these 
enzymes may also serve as biomarkers to identify the early 
stages of OA in dogs.
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